{"id":74917,"date":"2018-01-04T01:22:53","date_gmt":"2018-01-04T09:22:53","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2018\/01\/us-drug-firm-offers-cure-for-blindness-at-425000-an-eye"},"modified":"2018-01-09T20:02:30","modified_gmt":"2018-01-10T04:02:30","slug":"us-drug-firm-offers-cure-for-blindness-at-425000-an-eye","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2018\/01\/us-drug-firm-offers-cure-for-blindness-at-425000-an-eye","title":{"rendered":"US drug firm offers cure for blindness \u2013 at $425,000 an eye"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/us-drug-firm-offers-cure-for-blindness-at-425000-an-eye.jpg\"><\/a><\/p>\n<p>Gene therapy is not alone in commanding staggering sums, particularly when it comes to treatments for rare diseases. Soliris, a drug that treats a condition called paroxysmal nocturnal hemoglobinuria that attacks red blood cells, can cost up to $700,000 a year, while Elaprase, used in the treatment of Hunter syndrome, costs $500,000 a year.<\/p>\n<hr>\n<p>Spark Therapeutics says \u2018responsible price\u2019 for Luxturna gene therapy ensures access for patients with retinal defect.<\/p>\n<p><!-- Link: <a href=\"https:\/\/www.theguardian.com\/business\/2018\/jan\/03\/us-drug-firm-offers-cure-for-blindness-at-425000-an-eye\">https:\/\/www.theguardian.com\/business\/2018\/jan\/03\/us-drug-fir...000-an-eye<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gene therapy is not alone in commanding staggering sums, particularly when it comes to treatments for rare diseases. Soliris, a drug that treats a condition called paroxysmal nocturnal hemoglobinuria that attacks red blood cells, can cost up to $700,000 a year, while Elaprase, used in the treatment of Hunter syndrome, costs $500,000 a year. Spark [\u2026]<\/p>\n","protected":false},"author":417,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-74917","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/74917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/417"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=74917"}],"version-history":[{"count":1,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/74917\/revisions"}],"predecessor-version":[{"id":75021,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/74917\/revisions\/75021"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=74917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=74917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=74917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}